Hubei Goto Biopharm Co.,Ltd. (300966.SZ)
CNY 15.73
(-0.25%)
CNY 15.73
(-0.25%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 603.75 Million CNY | 81.92% |
| 2022 | 331.88 Million CNY | 786.1% |
| 2021 | -48.37 Million CNY | -143.66% |
| 2020 | 110.8 Million CNY | 527.53% |
| 2019 | 17.65 Million CNY | 11.88% |
| 2018 | 15.78 Million CNY | 32.84% |
| 2017 | 11.88 Million CNY | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 893.43 Million CNY | 23.37% |
| 2024 Q3 | 864.19 Million CNY | -3.27% |
| 2024 Q1 | 724.17 Million CNY | 19.94% |
| 2023 Q3 | 620.84 Million CNY | 6.2% |
| 2023 FY | 603.75 Million CNY | 81.92% |
| 2023 Q4 | 603.75 Million CNY | -2.75% |
| 2023 Q2 | 584.62 Million CNY | 15.56% |
| 2023 Q1 | 505.91 Million CNY | 52.44% |
| 2022 Q3 | 334.53 Million CNY | 256.89% |
| 2022 Q2 | 93.73 Million CNY | 53.83% |
| 2022 Q1 | 60.93 Million CNY | 225.97% |
| 2022 FY | 331.88 Million CNY | 786.1% |
| 2022 Q4 | 331.88 Million CNY | -0.79% |
| 2021 Q4 | -48.37 Million CNY | -348.75% |
| 2021 Q1 | 142.96 Million CNY | 29.03% |
| 2021 FY | -48.37 Million CNY | -143.66% |
| 2021 Q3 | 19.44 Million CNY | 294.87% |
| 2021 Q2 | -9.97 Million CNY | -106.98% |
| 2020 Q1 | 129.66 Million CNY | 634.36% |
| 2020 FY | 110.8 Million CNY | 527.53% |
| 2020 Q4 | 110.8 Million CNY | 0.0% |
| 2020 Q3 | - CNY | -100.0% |
| 2020 Q2 | 72.79 Million CNY | -43.86% |
| 2019 FY | 17.65 Million CNY | 11.88% |
| 2019 Q4 | 17.65 Million CNY | 0.0% |
| 2018 FY | 15.78 Million CNY | 32.84% |
| 2017 FY | 11.88 Million CNY | 0.0% |